Amgen (NASDAQ:AMGN) will report earnings after markets close on Tuesday, April 23rd. Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
Here is your Cheat Sheet to Amgen Earnings:
Earnings Expectations: Analysts expect earnings of $1.84 per share on revenues of $4.36 billion. Currently, the company’s P/E ratio stands at 19.47.
Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a profit of $1.72 to a profit $1.76. For the current year, the average estimate is a profit of $7.2, which is better than the estimate ninety days ago.
Here’s how Amgen has been performing on an annual basis:
|Revenue ($) in millions||15,000||14,640||15,050||15,580||17,260|
|Diluted EPS ($)||3.77||4.51||4.79||4.04||5.52|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||3,973||4,048||4,477||4,319||4,421|
|Diluted EPS ($)||1.09||1.48||1.61||1.41||1.02|
Amgen has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)